Evidence map›Paper›PMID 27405816›Full record

ReviewCurrent HIV/AIDS reports2016

Implementing Community Engagement for Combination Prevention: Lessons Learnt From the First Year of the HPTN 071 (PopART) Community-Randomized Study.

Musonda Simwinga, Virginia Bond, Nozizwe Makola, Graeme Hoddinott, Steve Belemu, Rhonda White, Kwame Shanaube, Janet Seeley, Ayana Moore, HPTN 071 (PopART) study team

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01900977 (Population Effects of Antiretroviral Therapy to Reduce HIV Transmission), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01900977 nacompletednot on this map

Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-randomized Trial of the Impact of a Combination Prevention Package on Population-level HIV Incidence in Zambia and South Africa

TypeinterventionalSponsorHIV Prevention Trials NetworkRan2014 to 2018Enrolled48,540ConditionsHIVArmsUniversal Testing with immediate ART, Universal Testing with ART eligibility according to National Guidelines, Standard of Care
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Musonda SimwingaZambart, School of Medicine, Ridgeway Campus, P.O. Box 50697, 10101, Lusaka, Zambia. musonda@zambart.org.zm.
Virginia BondZambart, School of Medicine, Ridgeway Campus, P.O. Box 50697, 10101, Lusaka, Zambia.
Nozizwe MakolaDepartment of Paediatrics and Child Health, Stellenbosch University (DTTC) Desmond Tutu TB Centre, Cape Town, South Africa.
Graeme HoddinottDepartment of Paediatrics and Child Health, Stellenbosch University (DTTC) Desmond Tutu TB Centre, Cape Town, South Africa.
Steve BelemuZambart, School of Medicine, Ridgeway Campus, P.O. Box 50697, 10101, Lusaka, Zambia.
Rhonda WhiteFHI360, Durham, NC, USA.
Kwame ShanaubeZambart, School of Medicine, Ridgeway Campus, P.O. Box 50697, 10101, Lusaka, Zambia.
Janet SeeleyDepartment of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine (LSHTM), London, UK.
Ayana MooreFHI360, Durham, NC, USA.
HPTN 071 (PopART) study team

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619PEPFAR
6 · The paper itself

Abstract

Key to the success of a HIV combination prevention strategy, including galvanizing the current push to roll out universal test and treat (UTT), is the involvement and buy-in of the populations that the strategy aims to reach. Drawing on the experiences of engaging with 21 communities in Zambia and South Africa in the design and implementation of a community-randomized study of combination HIV prevention including UTT, this paper reflects on the commitment to, approaches for and benefits of involving communities. Key lessons learnt include that all communities require continuous community engagement (CE) and engagement needs to be adapted to diverse local contexts. Intrinsic goals of CE, such as building trusting relationships between study stakeholders, are necessary precursors to instrumental goals which strengthen the research quality. Engaging the community for combination prevention requires that CE successfully bridges science and real life, paying attention to influences in the wider social landscape.

Indexed as

Behavior TherapyRandomized Controlled Trials as TopicAcquired Immunodeficiency SyndromeAdolescentAdultAnti-Retroviral AgentsCircumcision, MaleCommunity-Based Participatory ResearchCondomsFemaleHIV InfectionsHumansMaleMass ScreeningPatient Acceptance of Health CareProgram EvaluationAnti-Retroviral AgentsCommunity engagementCommunity participationCommunity-randomized trialHIV prevention

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.